It has been about a month since the last earnings report for Immunovant, Inc. (IMVT) . Shares have added about 13.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Immunovant due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Immunovant's Q1 Earnings Miss Estimates ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Num ...

Exhibit 99.1 Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 • Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) • Progressed development of lead asset IMVT-1402 with 3 Investigational New Drug (IND) applications expected to be active by calendar year end (December 31, 2024) • Progressed Graves' dise ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38906 IMMUNOVANT, INC. (Exact name of registrant as specified in its Charter) _____________________ (State or other jurisdiction ...

Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 NEW YORK, May 29, 2024 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024. "We are very excited about the immunology market evolution that we believe positions the ...

Neurology Clinical Development Updates: Immunovant designed the batoclimab MG trial to study the potential benefits of batoclimab across three important patient needs that we do not believe are addressed by other FcRn inhibitor MG development programs: 1) the potential benefits of high dose induction therapy, 2) continuous long-term therapy with a simple subcutaneous injection, and 3) multiple doses to potentially enable tailored, continuous therapy based on individual patient needs. Given the importance of ...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024. "We are very excited about the immunology market evolution that we believe positions the anti-FcRn mechanism to be the leading therapeutic class across a broad range of autoantibody-driven indications. Within the ...

Biohaven (BHVN) stock crashed Wednesday after the company's experimental protein-degrading drug — which could be used to treat a myriad of immune-related diseases — lagged investor expectations. X The company tested four doses of its drug, BHV-1300, which is meant to break down immunoglobulin G, or IgG, an autoantibody at the center of diseases like rheumatoid arthritis and myasthenia gravis. In healthy volunteers, the doses reduced IgG by up to 37%. Biohaven called the results "positive," noting that IgG l ...

Shares of Immunovant, Inc. (IMVT) have gained 0.1% over the past four weeks to close the last trading session at $29.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $49.56 indicates a potential upside of 68.6%. The average comprises 16 short-term price targets ranging from a low of $32 to a high of $57, with a standard deviation of $6.11. While the lowest estimate indicates ...

Immunovant, Inc. (IMVT) is a New York-based biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. The company currently has no marketed products in its commercial portfolio.Immunovant’s clinical-stage pipeline comprises its lead product candidate, batoclimab (formerly known as IMVT-1401), and a new candidate, IMVT-1402, which are being developed as a subcutaneous injection for the treatment of IgG-mediated autoimmune diseases.Let’s delve deeper to discuss ...